仑伐替尼和替雷利珠单抗联合介入治疗在中晚期肝癌患者中的应用效果  

Application effect of lenvatinib and tislelizumab combined with interventional therapy on patients with middle and advanced liver cancer

作　　者：李红卫 廖宝春 王博文 LI Hongwei;LIAO Baochun;WANG Bowen(Department of Drug and Equipment,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China;Department of Abdomen Surgery,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China)

机构地区：[1]赣州市肿瘤医院药械科,江西赣州341000 [2]赣州市肿瘤医院腹部外科,江西赣州341000

出　　处：《癌症进展》2025年第4期476-479,共4页Oncology Progress

摘　　要：目的探讨仑伐替尼和替雷利珠单抗联合介入治疗在中晚期肝癌患者中的应用效果。方法根据治疗方法的不同将83例中晚期肝癌患者分为对照组(n=40,介入治疗)和联合组(n=43,仑伐替尼和替雷利珠单抗联合介入治疗)。比较两组患者的临床疗效、肿瘤标志物[甲胎蛋白(AFP)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)]水平、肝功能指标[天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、白蛋白(ALB)、总胆红素(TBIL)]、甲状腺功能指标[促甲状腺激素(TSH)、游离甲状腺素(FT_(4))、游离三碘甲状腺原氨酸(FT_(3))]及不良反应发生情况。结果联合组患者的客观缓解率高于对照组,差异有统计学意义(P﹤0.05)。治疗后,两组患者AFP、CA19-9、CEA、AST、ALT、TBIL水平均低于本组治疗前,ALB、FT_(3)、FT_(4)水平均高于本组治疗前,联合组患者AFP、CA19-9、CEA、AST、ALT、TBIL水平均低于对照组,ALB、FT_(3)、FT_(4)水平均高于对照组,差异均有统计学意义(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论仑伐替尼和替雷利珠单抗联合介入治疗在中晚期肝癌患者中具有良好的临床疗效和一定的安全性。Objective To explore the application effect of lenvatinib and tislelizumab combined with interventional therapy on patients with middle and advanced liver cancer.Method According to different treatment methods,83 patients with middle and advanced liver cancer were divided into control group(n=40,interventional therapy)and combination group(n=43,lenvatinib and tislelizumab combined with interventional therapy).The clinical efficacy,tumor markers[alpha fetoprotein(AFP),carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)],liver function indexes[aspartate transaminase(AST),alanine aminotransferase(ALT),albumin(ALB),total bilirubin(TBIL)]and thyroid function indexes[thyroid-stimulating hormone(TSH),free thyroxine(FT_(4)),free triiodothyronine(FT_(3))]and adverse reaction were compared between the two groups.Result The objective response rate of the combination group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of AFP,CA19-9,CEA,AST,ALT and TBIL in both groups were lower than those before treatment,the levels of ALB,FT_(3) and FT_(4) were higher than those before treatment,and the levels of AFP,CA19-9,CEA,AST,ALT and TBIL in the combination group were lower than those in the control group,the levels of ALB,FT_(3) and FT_(4) were higher than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Lenvatinib and tislelizumab combined with interventional therapy has good clinical efficacy and certain safety in patients with middle and advanced liver cancer.

关 键 词：仑伐替尼 替雷利珠单抗 介入治疗 中晚期肝癌 客观缓解率 不良反应 

分 类 号：R735.7[医药卫生—肿瘤]